Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 871 to 880 of 1562 total matches.
A Vaccine for Rotavirus
The Medical Letter on Drugs and Therapeutics • May 21, 1999 (Issue 1053)
SITE: http://www.medletter.com
The Medical Letter, Vol. 41 (Issue 1053) May 21, 1999, p. 50
Copyright ...
The FDA has approved the marketing of RotaShield, a live oral vaccine for prevention of infantile rotavirus infection. Rotaviruses are segmented double-stranded RNA viruses that are the most common cause of severe diarrhea and dehydration in infants and young children.
In Brief: Sacubitril/Valsartan (Entresto) Expanded Indication
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
://medicalletter.org/TML-article-1619e
66
The Medical Letter ® Vol. 63 (1623) May 3, 2021
Medical
Letter sacubitril ...
The oral fixed-dose combination of the neprilysin
inhibitor sacubitril and the angiotensin receptor
blocker (ARB) valsartan (Entresto – Novartis) was
approved in 2015 to reduce the risk of cardiovascular
death and hospitalization for heart failure in adults with
chronic heart failure (NYHA Class II-IV) and reduced
ejection fraction (HFrEF; LVEF...
COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
, 2022.
The Medical Letter ® Vol. 64 (1652) June 13, 2022 vaccines Spikevax COVID-19 Comirnaty ...
The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19 vaccine. The mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are preferred for all persons without a contraindication.
In Brief: Over-the-Counter Narcan Nasal Spray
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
.
The Medical Letter ® Vol. 65 (1675) May 1, 2023 buprenorphine opioid dependence naltrexone Kloxxado opioid ...
The FDA has approved the over-the-counter (OTC)
sale of Narcan (Emergent), a nasal spray that delivers
4 mg of the opioid antagonist naloxone. Narcan nasal
spray has been available by prescription since 2015
for emergency treatment of opioid overdose. Generic
formulations of Narcan have also been approved; the
manufacturers of these products will be required to
switch them to OTC status and amend their labeling
accordingly. Kloxxado, an 8-mg naloxone nasal
spray, remains available only by prescription.
Med Lett Drugs Ther. 2023 May 1;65(1675):72 doi:10.58347/tml.2023.1675e | Show Introduction Hide Introduction
In Brief: Once-Monthly Lecanemab (Leqembi) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025 (Issue 1726)
.
The Medical Letter ® Vol. 67 (1726) April 14, 2025 lecanemab Alzheimer's disease Leqembi ...
The amyloid beta-directed monoclonal antibody
lecanemab-irmb (Leqembi – Eisai/Biogen) has now
been approved by the FDA for once-monthly use for
treatment of Alzheimer's disease (AD) in patients with
mild cognitive impairment (MCI) or mild dementia. It
was previously approved only for administration once
every 2 weeks. Now, lecanemab can be given every
4 weeks after an 18-month initiation phase of
biweekly administration.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):64 doi:10.58347/tml.2025.1726f | Show Introduction Hide Introduction
In Brief: Low-Dose Chlorthalidone (HemiClor) for Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
dose without having to split a
higher-strength tablet.
The Medical Letter ® Vol. 67 (1733) July 21 ...
The FDA has approved a 12.5-mg tablet formulation
of the thiazide-like diuretic chlorthalidone (HemiClor –
Ingenus) for treatment of hypertension. Chlorthalidone
has been available for years in 15-, 25-, and 50-mg
tablets (Thalitone, and generics) and in fixed-dose
combinations with azilsartan medoxomil (Edarbyclor)
and atenolol (Tenoretic, and generics).
Med Lett Drugs Ther. 2025 Jul 21;67(1733):118 doi:10.58347/tml.2025.1733e | Show Introduction Hide Introduction
Drugs for Bacterial Infections
Treatment Guidelines from The Medical Letter • Jul 01, 2013 (Issue 131)
from The Medical Letter • Vol. 11 (Issue 131) • July 2013
spp. is suspected, a combination of clindamycin ...
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results of
susceptibility studies, clinical trials, and the opinions
of Medical Letter reviewers. Tables 1 and 2 list the usual
dosages of antibacterial drugs.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
Expanded Table: Some Vaccines for Adults online
The Medical Letter ® Vol. 64 (1661) October 17, 2022
162 ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
activity.
154
The Medical Letter ® Vol. 60 (1556) September 24, 2018
Table 2. Drugs for Herpes Simplex ...
The recommendations for treatment of varicella-zoster
virus (VZV) and herpes simplex virus (HSV)
infections are listed in tables 1 and 2. Vaccination
against VZV was reviewed in a previous issue.
Antimicrobial Prophylaxis for Surgery
The Medical Letter on Drugs and Therapeutics • May 23, 2016 (Issue 1495)
of this material is strictly prohibited.
For further information call: 800-211-2769
64
The Medical Letter ® Vol ...
Antimicrobial prophylaxis can decrease the
incidence of postoperative surgical site infection
after some procedures. Since the last Medical Letter
article on this subject, consensus guidelines have
been published. Recommendations for prophylaxis
in specific surgical procedures are listed in Table 1.
